Shares of Navidea Biopharmaceuticals soared 4.94% at the last check-in extended trading at $1.7. During the previous session, Navidea shares closed at $1.62, -1.22%, or -$0.02. The share price of NAVB stock fluctuated between $1.58 and $1.65 throughout the day. NAVB lost -36.22% in the last six months, and -34.94% in the last three months. In the absence of recent news, it is plausible that recent news may have contributed to the rise of NAVB stock.
Recent development:
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Biopharmaceutical company Navidea develops precision immunodiagnostics and immunotherapeutics. Several precision-targeted products are being developed based on NAVB’s Manocept platform to improve patient care by identifying sites and pathways of disease and enable more accurate diagnostics, targeted treatment, and improved clinical decision-making.
Read More
- Looking For The Best Stocks To Buy For 2021? 3 Electric Vehicle Stocks To Watch
- Top 3 Cosmetics Stocks in the market
An upcoming poster presentation of Navidea’s preclinical results of its targeted cancer immunotherapeutic agent will take place at the New York Academy of Sciences’s (NYAS) Frontiers in Cancer Immunotherapy Symposium in 2021.
It will take place virtually from Wednesday, May 12 until Friday, May 14, 2021, at 5:00 PM EDT. The poster will be titled:
“Targeted Delivery of Doxorubicin (DOX) to Tumor-Associated Macrophages (TAMs) Beneficially Alters the Tumor Immune Microenvironment and Synergizes the Activity of Anti-CTLA4.”
NAVB’s CD206-targeted therapeutic construct containing doxorubicin linked to its dextran backbone (Man-Dox) demonstrated synergistic effects on tumor growth inhibition with a standard immunotherapeutic in vitro and in animal models. CD206, a receptor on macrophages that binds mannose, is the cellular target of Navidea’s Man-Dox agent.
Additionally,
TAMs that express CD206 are key regulators of the tumor microenvironment. This provides a target for immunotherapies by Navidea (NAVB) aimed at rallying the body’s own immune system against cancer.